What is NGS Genotyping and Why It Matters for Lung Cancer Immune Surveillance
Next-generation sequencing (NGS) genotyping is a high-throughput method for identifying genomic variations—single nucleotide variants, indels, copy number alterations, and structural rearrangements—in targeted regions, exomes, or whole genomes. In the context of lung cancer, tumor suppressor gene mutations (e.g., TP53, STK11, KEAP1) are key determinants of immune evasion and response to immunotherapy. NGS genotyping enables precise detection of these alterations, providing a genomic foundation for understanding how genotype influences the extent and mode of immune surveillance.
Our service integrates NGS genotyping with immune microenvironment analysis and spatial transcriptomics, allowing researchers to correlate somatic mutations with immune cell infiltration, checkpoint expression, and tumor–immune interactions. By combining genomic profiling with spatial gene expression data, we help uncover mechanisms of immune evasion and identify novel therapeutic targets for genotype-guided immunotherapies.
We offer flexible NGS workflows—from targeted gene panels to whole-exome sequencing—tailored to your research question. Each project is supported by rigorous QC metrics, bioinformatics analysis, and a clear report of actionable findings.
NGS Genotyping Service Offerings
Targeted NGS Panels for Tumor Suppressor Genes
Design custom panels covering key tumor suppressor genes and immune-related loci. Multiplex amplification or hybrid capture approaches ensure high on-target rates and uniform coverage, even in FFPE samples.
Comprehensive Genomic Profiling (Whole-Exome / Whole-Genome)
For unbiased discovery, we provide whole-exome or low-pass whole-genome sequencing. Detect coding mutations, splice variants, and copy number alterations across the genome, enabling correlation with immune microenvironment features.
Integrated Immune Microenvironment Analysis
Combine NGS genotyping with spatial transcriptomics or bulk RNA-seq to map how tumor suppressor genotypes correlate with immune cell composition, checkpoint expression, and spatial organization. Mechanistic insights into immune evasion as scoped per project.
Our NGS Genotyping Workflow
High-quality DNA is extracted from tissue (FFPE or fresh-frozen) or blood samples. Concentration, purity, and integrity are assessed via fluorometry and gel electrophoresis before proceeding.
Depending on the approach (targeted capture or amplicon-based), genomic DNA is fragmented, end-repaired, and ligated with sequencing adapters. Unique dual indexes allow multiplexing. Libraries are quantified and size-selected to ensure optimal cluster density.
Libraries are loaded onto Illumina or compatible platforms for paired-end sequencing. Run parameters (read length, depth) are scoped per project to achieve the required sensitivity for variant detection—commonly 200×–500× for targeted panels, >100× for exomes.
Raw data are processed through a validated pipeline: alignment to the reference genome, variant calling (SNVs, indels, CNVs), annotation, and filtering. Results are delivered in VCF/MAF format with an interpretative report highlighting relevant tumor suppressor gene mutations and potential immune implications.
Project Scope and Deliverables
| Item | Description |
|---|---|
| Sequencing Depth | Typically 200×–500× for targeted panels; ≥100× for whole-exome (scoped per project) |
| Variant Detection | Single nucleotide variants, insertions/deletions, and copy number alterations identified using ensemble callers with custom filtering |
| Bioinformatics Report | Annotated VCF/MAF files, coverage statistics, variant interpretation with ClinVar/OncoKB references, and tumor suppressor gene summary |
Why Choose Our NGS Genotyping Service?
Multi-Technology Flexibility
We support a range of genotyping technologies—PCR, Sanger sequencing, NGS (targeted, exome, genome), and microarrays—allowing you to select the most appropriate method for your research question and sample type.
Integrated Spatial & Immune Context
Our service combines NGS genotyping with spatial transcriptomics and immune microenvironment analysis, enabling you to directly link tumor suppressor genotypes with immune cell infiltration, checkpoint expression, and evasion mechanisms.
Rigorous Quality Control
Every step—from nucleic acid extraction through library preparation and sequencing—includes built-in QC checkpoints. Metrics such as DNA integrity, library concentration, and sequencing coverage are monitored to ensure reliable results.
Flexible Sample Compatibility
We accept a variety of sample types including FFPE tissue, fresh-frozen tissue, and blood. Protocols are optimized for each sample format to maximize yield and data quality.
Recent Advances in NGS Technology
Advance Your Lung Cancer Immunogenomics Research
Partner with our experienced team to integrate NGS genotyping and tumor microenvironment analysis. We tailor each project to your specific genes of interest, sample types, and desired depth. Get in touch to discuss your project scope and timeline.